OR WAIT 15 SECS
Catalent’s FlexDirect service offers sponsors multiple delivery options from a single inventory.
Catalent has launched , a new direct-to-patient service for clinical trials, which offers trial sponsors the choice of site-to-patient distribution, pharmacy-to-patient service, or a combination of these services with standard
The company’s pharmacy and standard distribution services are located in the same facility; clinical supplies distributed to clinical sites or directly to patients to originate from a single location using a single inventory, the company reported in a Jan. 14, 2020 press statement.
The direct-to-patient distribution of clinical supplies can support recruitment and retention of patients by delivering treatments directly to patient homes, improving convenience, and reducing the number of clinical visits, Catalent reports.
Site-to-patient services are available in the United States and Europe. Pharmacy-to-patient services are accessible in the US via Catalent’s on-site pharmacy in Philadelphia.
The Philadelphia facility, the largest site in the company’s global clinical supply network, has 200,000 sq. ft. of storage, packaging, and distribution space. A $5.5-million expansion program completed in 2019 added storage space, cold chain packaging areas, and a clinical label design and printing area.
“The nature of clinical trials has evolved, but the needs for a trial to maintain patient engagement and ensure dosing regimens are adhered to remain paramount, and direct-to-patient supply reduces the burden of patients to visit clinical sites and maintain participation,” explained Kristen DeVito, global director clinical supply services. “FlexDirect increases the options available to study sponsors and offers increased flexibility in distribution, reducing the strain on clinical sites by offering a pharmacy-based service and promoting patient retention.”